Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth Sells 7,500 Shares

Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.16, for a total value of $136,200.00.

Shares of DNLI stock traded down $0.70 during trading hours on Thursday, reaching $18.94. 5,034 shares of the company’s stock were exchanged, compared to its average volume of 350,351. The company has a market cap of $1.68 billion, a P/E ratio of -48.00 and a beta of 2.20. The company’s 50 day moving average is $18.87 and its two-hundred day moving average is $21.25. Denali Therapeutics Inc has a 1 year low of $13.78 and a 1 year high of $28.86. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.65 and a quick ratio of 10.66.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Tuesday, August 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.15). The business had revenue of $4.20 million for the quarter, compared to analysts’ expectations of $4.52 million. Denali Therapeutics had a negative return on equity of 11.03% and a negative net margin of 40.78%. As a group, analysts predict that Denali Therapeutics Inc will post -2.02 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the company. State Board of Administration of Florida Retirement System raised its stake in shares of Denali Therapeutics by 19.3% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 20,555 shares of the company’s stock worth $427,000 after buying an additional 3,330 shares in the last quarter. Xact Kapitalforvaltning AB purchased a new position in Denali Therapeutics in the 2nd quarter valued at approximately $210,000. Baillie Gifford & Co. increased its stake in Denali Therapeutics by 18.3% in the 2nd quarter. Baillie Gifford & Co. now owns 7,407,229 shares of the company’s stock valued at $153,773,000 after purchasing an additional 1,145,003 shares in the last quarter. Chicago Equity Partners LLC purchased a new position in Denali Therapeutics in the 2nd quarter valued at approximately $2,438,000. Finally, Acadian Asset Management LLC increased its stake in Denali Therapeutics by 136.7% in the 2nd quarter. Acadian Asset Management LLC now owns 11,650 shares of the company’s stock valued at $241,000 after purchasing an additional 6,728 shares in the last quarter. 73.91% of the stock is owned by institutional investors and hedge funds.

Several analysts have commented on the company. TheStreet downgraded Denali Therapeutics from a “c-” rating to a “d” rating in a research note on Thursday, June 13th. ValuEngine raised Denali Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 4th. Zacks Investment Research downgraded Denali Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 7th. BTIG Research assumed coverage on Denali Therapeutics in a research note on Friday, August 9th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Morgan Stanley set a $32.00 price objective on Denali Therapeutics and gave the company a “buy” rating in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $27.33.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Recommended Story: Stock Symbols Definition, Examples, Lookup

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit